Morpholino(1-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)piperidin-3-yl)methanone

Catalog No. :
ACKOTR013
CAS No. :
2134721-38-1
Molecular Formula :
C14H23F3N2O3
Molecular Weight :
324.34

IUPAC Name:morpholino(1-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)piperidin-3-yl)methanone

Morpholino(1-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)piperidin-3-yl)methanone structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$852.00Login to see priceInquiryInquiry
1g97%$1704.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameMorpholino(1-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)piperidin-3-yl)methanone
IUPAC Namemorpholino(1-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)piperidin-3-yl)methanone
MDL No.MFCD32220399
Molecular FormulaC14H23F3N2O3
Molecular Weight324.34
SMILESO=C(N1CCOCC1)C2CN(CC(C)(O)C(F)(F)F)CCC2
InChI KeyCZVCXBVJQVOHEA-UHFFFAOYSA-N
SynonymMorpholino[1-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-3-piperidyl]methanone;Methanone, 4-morpholinyl[1-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-3-piperidinyl]-
CAS No.2134721-38-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACKOTR013 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACKOTR013 route product structure diagram
    ACKOTR0132134721-38-1
Inquiry

2. ACKOTR013 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACKOTR013 route product structure diagram
    ACKOTR0132134721-38-1
Inquiry

Comments (0)